Goldberg Law PC (http://www.Goldberglawpc.com) announces that it is investigating claims of potential misrepresentations by Vital Therapies, Inc. (“Vital Therapies” or the “Company”) (NASDAQ: VTL). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased or otherwise acquired Vital Therapies shares and would like more information regarding the investigation, we advise you to contact Michael Goldberg or Brian Schall of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

On July 14, 2015, the online investing site Seeking Alpha published a report alleging that Vital Therapies’ representations regarding the 90 day overall survival rate for those treated with the Company's Extracorporeal Liver Assist Device ("ELAD") were very misleading, as they included data from a patient who received a liver transplant, while no similar patient in the control group had received a transplant. The report alleges that this fact was not disclosed in any of the Company's prior disclosures concerning the Phase 2 VTI-206 study of ELAD. When the truth was revealed to the public, the stock dropped causing investors harm.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.